Literature DB >> 870794

Renal effects on serum gastric inhibitory polypeptide (GIP).

T M O'Dorisio, K R Sirinek, E L Mazzaferri, S Cataland.   

Abstract

Fasting and meal-stimulated serum immunoreactive gastric inhibitory polypeptide (GIP) concentrations were measured in normal subjects and in uremic patients undergoing chronic hemodialysis. Mean fasting GIP was higher in the uremic patients (1006 +/- 145 (SE) pg/ml) than in the normal control subjects (132 +/- 31 pg/ml, p less than 0.001). Also, postcibal absolute and incremental serum GIP concentrations between 15 and 180 min were greater (p less than 0.05) in the uremic patients than in the control subjects; in the former they failed to return to fasting levels 180 min after the meal. In a second study, using anesthetized normal dogs, simultaneous renal arterial and venous serum GIP concentrations were measured during an intraduodenal perfusion of glucose. The renal arterial-venous (A-V) GIP gradient became greater as serum arterial GIP concentrations increased. The correlation between renal A-V GIP gradient and renal arterial GIP concentration was quite good (r = 0.85), with a 39% maximum mean A-V reduction in serum GIP concentrations observed across the kidney. This large renal A-V GIP gradient observed under nonsteady conditions suggests that the kidney may be an important site for the removal of GIP from the circulation. Thus, the higher than normal fasting and stimulated serum GIP concentrations observed in uremic patients can be attributed, at least in part, to a loss of the renal extraction mechanism for GIP.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 870794     DOI: 10.1016/0026-0495(77)90086-5

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  7 in total

1.  Elevated plasma motilin concentrations in chronic renal disease.

Authors:  R S McLeod; N S Track; L E Reynolds
Journal:  Can Med Assoc J       Date:  1979-08-04       Impact factor: 8.262

2.  Effect of renal failure on gastrointestinal hormones.

Authors:  J Hansky
Journal:  World J Surg       Date:  1979-08-31       Impact factor: 3.352

3.  Basal and nutrient-stimulated pancreatic and gastrointestinal hormone concentrations in type-1-diabetic patients after successful combined pancreas and kidney transplantation.

Authors:  M A Nauck; M Büsing; C Orskov; E G Siegel; J Talartschik; A Baartz; T Baartz; H Hölzer; U T Hopt; R Ebert
Journal:  Clin Investig       Date:  1992-01

4.  Effect of renal failure or portacaval shunt on release of neurotensin in man.

Authors:  E R Eaves; J Hansky
Journal:  Dig Dis Sci       Date:  1987-01       Impact factor: 3.199

5.  Preserved incretin effect in type 1 diabetic patients with end-stage nephropathy treated by combined heterotopic pancreas and kidney transplantation.

Authors:  M A Nauck; M Büsing; C Orskov; E G Siegel; J Talartschik; A Baartz; T Baartz; U T Hopt; H D Becker; W Creutzfeldt
Journal:  Acta Diabetol       Date:  1993       Impact factor: 4.280

Review 6.  The gastrointestinal endocrine system.

Authors:  N S Track
Journal:  Can Med Assoc J       Date:  1980-02-09       Impact factor: 8.262

7.  Enhanced cAMP generation and insulin-releasing potency of two novel Tyr1-modified enzyme-resistant forms of glucose-dependent insulinotropic polypeptide is associated with significant antihyperglycaemic activity in spontaneous obesity-diabetes.

Authors:  Victor A Gault; Peter R Flatt; Clifford J Bailey; Patrick Harriott; Brett Greer; Mark H Mooney; Finbarr P M O'harte
Journal:  Biochem J       Date:  2002-11-01       Impact factor: 3.857

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.